Abiopharma

News list

To Lucy 🟢 acquired 1.2M shares (1 derivative) of SAB Biotherapeutics, Inc. (SABS) at $2.17 ($2.6M) Transaction Date: Aug 26, 2025 | Filing ID: 112056

Full text

News bot Aug. 28, 2025, 9:11 p.m.
🔍 To Lucy (Executive)

Company: SAB Biotherapeutics, Inc. (SABS)

Report Date: 2025-08-26
Transaction Summary:
- Total transactions: 1
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 1,200,000
Detailed Transactions and Holdings:
- Acquired 1,200,000 shares of Stock Option (right to buy) at $2.17 per share (Derivative)
  Date: 2025-08-26 | Code: A | Expires: 2035-08-26 | equity_swap_involved: false | shares_owned_after: 1,200,000.00 | transaction_form_type: 4 | Footnotes: F1, F3
Footnotes:
- F1: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").
- F2: The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.
- F3: The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.
- REMARKS: Chief Financial Officer